Table 1 Demographic data, and clinical characteristics.
From: Randomized controlled trial of bromelain and alpha-lipoic acid in breast conservative surgery
A (n = 39; 34.2%) | B (n = 37; 32.5%) | C (n = 38; 33.3%) | A vs C P* | B vs C P* | A vs B P* | |
|---|---|---|---|---|---|---|
Age | 56.5 ± 9.4 | 57.2 ± 10.2 | 54.8 ± 11.2 | 0.47 | 0.34 | 0.79 |
Palpable mass | 6 (15.4) | 7 (18.9) | 6 (15.8) | 1 | 0.77 | 0.78 |
ASA | ||||||
1–2 | 34 (87.2) | 34 (91.9) | 30 (78.9) | 0.37 | 0.19 | 0.71 |
3–4 | 5 (12.8) | 3 (8.1) | 8 (21.1) | 0.38 | 0.19 | 0.71 |
BMI | ||||||
< 30 | 24 (61.5) | 20 (54.1) | 19 (50) | 0.36 | 0.82 | 0.64 |
≥ 30 | 15 (38.5) | 17 (45.9) | 19 (50) | 0.36 | 0.82 | 0.64 |
Previous breast surgery | 1 (2.6) | 1 (2.7) | 2 (5.3) | 0.61 | 1 | 1 |
Cardiological disease | 12 (30.8) | 15 (40.5) | 14 (37.8) | 0.63 | 0.81 | 0.48 |
Pulmonary disease | 1 (2.6) | 2 (5.4) | 0 (0) | 1 | 0.24 | 0.61 |
Renal disease | 0 (0) | 0 (0) | 1 (2.6) | 0.49 | 1 | 1 |
Hepatic disease | 0 (0) | 0 (0) | 1 (2.6) | 0.49 | 1 | 1 |
Other types of cancer | 2 (5.1) | 0 (0) | 2 (5.4) | 1 | 0.22 | 0.49 |
Anticoagulant/antiplatelet drugs | 3 (7.7) | 4 (10.8) | 1 (2.7) | 0.61 | 0.2 | 0.71 |
Corticosteroids/immunosuppressant drugs | 2 (5.1) | 0 (0) | 1 (2.7) | 1 | 1 | 0.49 |
NAC | 1 (0.9) | 0 (0) | 0 (0) | 1 | 1 | 1 |
Previous neck/chest radiotherapy | 0 (0) | 0 (0) | 1 (2.6) | 0.49 | 1 | 1 |
